It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented preclinical data for their bispecific antibody (bsAb), IBI-334, against B7-H3 and EGFR.
Kinase inhibitors have emerged as crucial cancer therapeutics due to the involvement of kinases in cancer signaling. At the AACR, Neosome Life Sciences LLC has provided data on their kinase inhibitor NEOS-223 for the potential treatment of tumors. The compound was tested in several cancer cell types, as well as in in vivo cancer models in mice.
As with most common diseases of the developed world, aging is the major risk factor for developing cancer. Most of the half-dozen hallmarks of precancer that were published last week by investigators from Vanderbilt University and the Fred Hutchinson Cancer Research Center are also hallmarks of aging.
Unfortunately, scientists reported at the American Association for Cancer Research’s (AACR) 2024 annual meeting this week that accelerated aging is increasing, and may be driving an increase in early-onset cancers.
Additional early-stage research and drug discovery news in brief, from: Alzecure Pharma, Asher Biotherapeutics, Cantargia, Genprex, JD Bioscience, Surrozen.
Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small activating RNA (RNAa) therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.
Nanjing Zhongrui Medicine Co. Ltd. has described protein phosphatase 2A (PP2A) activators reported to be useful for the treatment of Alzheimer’s disease.
Scientists at Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have identified tetracyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.
RSS
